The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA)
The international recommendations «Treat to target» (T2T) underline the greatest importance of treatment strategy for the success of treating rheumatoid arthritis (RA). Evaluation of the efficiency of this approach obviously requires special strategic studies with an adaptive design, which substanti...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2013-04-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/775 |
| _version_ | 1797862782375297024 |
|---|---|
| author | Dmitri Evgenyevich Karateev E L Luchikhina Yu V Muravyev N V Demidova G I Grineva D S Novikova E N Aleksandrova A A Novikov A V Smirnov A V Volkov A S Avdeyeva E V Lopareva Yu A Olyunin G V Lukina T V Popkova E L Nasonov |
| author_facet | Dmitri Evgenyevich Karateev E L Luchikhina Yu V Muravyev N V Demidova G I Grineva D S Novikova E N Aleksandrova A A Novikov A V Smirnov A V Volkov A S Avdeyeva E V Lopareva Yu A Olyunin G V Lukina T V Popkova E L Nasonov |
| author_sort | Dmitri Evgenyevich Karateev |
| collection | DOAJ |
| description | The international recommendations «Treat to target» (T2T) underline the greatest importance of treatment strategy for the success of treating rheumatoid arthritis (RA). Evaluation of the efficiency of this approach obviously requires special strategic studies with an adaptive design, which substantially differ from classical randomized clinical trials and are much closer to clinical practice. To date, there are only single publications on the practical application of the T2T recommendations, there is a problem in the choice of effectiveness criteria and there are a number of other important problems associated with the introduction of these recommendations. The Russian study REMARCA is to answer these questions. Its design focuses on the practical adaptation of the T2T strategy to treat patients with earlyand extended-stage active RA who have poor prognostic factors, by using subcutaneous methotrexate and genetically engineered biological agents (GEBA). Preliminary analysis shows that therapy according to the REMARCA protocol is successful in the majority of patients. The high rate of low RA activity and remission has been achieved during subcutaneous methotrexate monotherapy. The patients who need GEBA to be incorporated may be initially more resistant to therapy. The patients with early RA have better chances of successful T2T therapy than those with extended-stage RA. |
| first_indexed | 2024-04-09T22:25:08Z |
| format | Article |
| id | doaj.art-689efa77aeab4a5dad6e6090ff4901dd |
| institution | Directory Open Access Journal |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| last_indexed | 2024-04-09T22:25:08Z |
| publishDate | 2013-04-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj.art-689efa77aeab4a5dad6e6090ff4901dd2023-03-22T13:45:48ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922013-04-0151211712510.14412/1995-4484-2013-637715The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA)Dmitri Evgenyevich KarateevE L LuchikhinaYu V MuravyevN V DemidovaG I GrinevaD S NovikovaE N AleksandrovaA A NovikovA V SmirnovA V VolkovA S AvdeyevaE V LoparevaYu A OlyuninG V LukinaT V PopkovaE L NasonovThe international recommendations «Treat to target» (T2T) underline the greatest importance of treatment strategy for the success of treating rheumatoid arthritis (RA). Evaluation of the efficiency of this approach obviously requires special strategic studies with an adaptive design, which substantially differ from classical randomized clinical trials and are much closer to clinical practice. To date, there are only single publications on the practical application of the T2T recommendations, there is a problem in the choice of effectiveness criteria and there are a number of other important problems associated with the introduction of these recommendations. The Russian study REMARCA is to answer these questions. Its design focuses on the practical adaptation of the T2T strategy to treat patients with earlyand extended-stage active RA who have poor prognostic factors, by using subcutaneous methotrexate and genetically engineered biological agents (GEBA). Preliminary analysis shows that therapy according to the REMARCA protocol is successful in the majority of patients. The high rate of low RA activity and remission has been achieved during subcutaneous methotrexate monotherapy. The patients who need GEBA to be incorporated may be initially more resistant to therapy. The patients with early RA have better chances of successful T2T therapy than those with extended-stage RA.https://rsp.mediar-press.net/rsp/article/view/775rheumatoid arthritistreat to targetremarca studymethotrexategenetically engineered agents |
| spellingShingle | Dmitri Evgenyevich Karateev E L Luchikhina Yu V Muravyev N V Demidova G I Grineva D S Novikova E N Aleksandrova A A Novikov A V Smirnov A V Volkov A S Avdeyeva E V Lopareva Yu A Olyunin G V Lukina T V Popkova E L Nasonov The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) Научно-практическая ревматология rheumatoid arthritis treat to target remarca study methotrexate genetically engineered agents |
| title | The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) |
| title_full | The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) |
| title_fullStr | The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) |
| title_full_unstemmed | The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) |
| title_short | The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA) |
| title_sort | first russian strategic study of pharmacotherapy for rheumatoid arthritis remarca |
| topic | rheumatoid arthritis treat to target remarca study methotrexate genetically engineered agents |
| url | https://rsp.mediar-press.net/rsp/article/view/775 |
| work_keys_str_mv | AT dmitrievgenyevichkarateev thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT elluchikhina thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT yuvmuravyev thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT nvdemidova thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT gigrineva thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT dsnovikova thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT enaleksandrova thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT aanovikov thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT avsmirnov thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT avvolkov thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT asavdeyeva thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT evlopareva thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT yuaolyunin thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT gvlukina thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT tvpopkova thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT elnasonov thefirstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT dmitrievgenyevichkarateev firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT elluchikhina firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT yuvmuravyev firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT nvdemidova firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT gigrineva firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT dsnovikova firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT enaleksandrova firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT aanovikov firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT avsmirnov firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT avvolkov firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT asavdeyeva firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT evlopareva firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT yuaolyunin firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT gvlukina firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT tvpopkova firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca AT elnasonov firstrussianstrategicstudyofpharmacotherapyforrheumatoidarthritisremarca |